Armstrong Mark, Morgan Justin, Kazey Olena, Freeman Kevin, Norton Robert
Pathology Queensland, Townsville University Hospital, Townsville, Queensland, Australia.
PathWest Laboratory Medicine, Nedlands, Western Australia, Australia.
Microbiol Spectr. 2023 Mar 27;11(2):e0494922. doi: 10.1128/spectrum.04949-22.
Melioidosis caused by Burkholderia pseudomallei causes significant morbidity and mortality in Southeast Asia and northern Australia. Clinical manifestations remain diverse, including localized skin infection, pneumonia, and chronic abscess formation. Culture remains the gold standard of diagnosis, with serology and antigen detection tests playing a role if culture is unfeasible. Serologic diagnosis remains challenging, with limited standardization across different assays. In areas of endemicity, high rates of seropositivity have been documented. The indirect hemagglutination assay (IHA) is one of the more widely used serologic tests in these areas. In Australia, only three centers perform the test. Annually, laboratory A, laboratory B, and laboratory C perform approximately 1,000, 4,500, and 500 tests, respectively. A comparison of a total of 132 sera was analyzed from the routine quality exchange program between these centers from 2010 until 2019. Overall, 18.9% of sera tested had an interpretative discrepancy between laboratories. This study found significant discrepant results between three Australian centers offering the melioidosis indirect hemagglutination assay (IHA), despite testing the same samples. We have highlighted that the IHA is a nonstandardized test, which had different source antigens at each of the different laboratories. Melioidosis is a global disease, is associated with significant mortality, and is perhaps under recognized. It is likely to have increasing impact with changing weather patterns. The IHA has been used frequently as an adjunct to the diagnosis of clinical disease and is the mainstay of determining seroprevalence within populations. Despite its relative ease of use, especially in low resource settings, our study highlights the significant limitations of the melioidosis IHA. It has wide ranging implications, serving as an impetus for developing better diagnostic tests. This study is of interest to practitioners and researchers working in the various geographic regions affected by melioidosis.
由伯克霍尔德菌引起的类鼻疽在东南亚和澳大利亚北部导致了显著的发病率和死亡率。其临床表现多样,包括局部皮肤感染、肺炎和慢性脓肿形成。培养仍然是诊断的金标准,若无法进行培养,血清学和抗原检测试验也能发挥作用。血清学诊断仍然具有挑战性,不同检测方法之间的标准化程度有限。在流行地区,已记录到较高的血清阳性率。间接血凝试验(IHA)是这些地区使用较广泛的血清学检测方法之一。在澳大利亚,只有三个中心开展该检测。每年,实验室A、实验室B和实验室C分别进行约1000次、4500次和500次检测。对2010年至2019年这些中心之间常规质量交换项目中的总共132份血清进行了分析比较。总体而言,检测的血清中有18.9%在各实验室之间存在解释差异。本研究发现,尽管检测的是相同样本,但提供类鼻疽间接血凝试验(IHA)的三个澳大利亚中心之间存在显著的差异结果。我们强调IHA是一种未标准化的检测方法,每个不同实验室的来源抗原都不同。类鼻疽是一种全球性疾病,与显著的死亡率相关,可能未得到充分认识。随着气候模式的变化,其影响可能会增加。IHA经常被用作临床疾病诊断的辅助手段,也是确定人群血清流行率的主要方法。尽管其相对易于使用,尤其是在资源匮乏的环境中,但我们的研究突出了类鼻疽IHA的显著局限性。它具有广泛的影响,为开发更好的诊断测试提供了动力。本研究对于在受类鼻疽影响的各个地理区域工作的从业者和研究人员具有参考价值。